Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Advisory Committee Waivers Reflect Recruitment Challenges

Executive Summary

Recent waivers allowing the participation of outside experts at drug-related advisory committee meetings reflect FDA's difficulties in finding qualified individuals to provide advice on specialized topics.

You may also be interested in...

Gastroenterology Endpoints To Get Four-Day Series Of FDA Workshops

One day each will be devoted to eosinophilic esophagitis, pediatric and adult inflammatory bowel disease, and parenteral nutrition-associated liver disease, Sept. 19, 20, 21 and 24, in that order.

Conflict-Of-Interest Policy Relaxation For FDA Cmtes. Could Be Easy PDUFA Add-on

FDA Commissioner Margaret Hamburg’s willingness to explore changes in conflict-of-interest policies for advisory committee members, coupled with a push for reforms by industry and lawmakers, suggests a relaxation of current screening requirements could become an easy add-on to the Prescription Drug User Fee Act reauthorizing legislation in 2012.

FDA Gains No Impartiality Benefit From Conflict-Of-Interest Policy, Advocates Say

Friends of Cancer Research cites an FDA-sponsored study to argue that agency adherence to an advisory committee conflict-of-interest policy that is stricter than required by law does not increase the impartiality of panel members’ recommendations.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts